Notices. DEPARTMENT OF HEALTH AND HUMAN SERVICES

517 words·~2 min read·/register/2022/02/07/2022-02469

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. *Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel;

NIH Support for Conferences and Scientific Meetings. *Date:* March 4, 2022. *Time:* 1:00 p.m. to 2:00 p.m. *Agenda:* To review and evaluate grant applications. *Place:* National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). *Contact Person:* Gerald L. McLaughlin, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892,

(301)827-5819, *gm145a@nih.gov.* *Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel; Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3 Clinical Trial Optional). *Date:* March 9, 2022. *Time:* 9:00 a.m. to 4:00 p.m. *Agenda:* To review and evaluate grant applications. *Place:* National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). *Contact Person:* Preethy Nayar, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, 301-443-4577, *nayarp2@csr.nih.gov.* *Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel; SEP for Centers Review. *Date:* March 9, 2022. *Time:* 10:00 a.m. to 5:00 p.m. *Agenda:* To review and evaluate grant applications. *Place:* National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). *Contact Person:* Sheila Pirooznia, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892,

(301)496-9350, *sheila.pirooznia@nih.gov.* *Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel; for Avenir Review. *Date:* March 21, 2022. *Time:* 3:00 p.m. to 4:00 p.m. *Agenda:* To review and evaluate grant applications. *Place:* National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). *Contact Person:* Ipolia R. Ramadan, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892,

(301)827-4471, *ramadanir@mail.nih.gov.* (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: February 1, 2022. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022-02469 Filed 2-4-22; 8:45 am]